호흡기질환 검사 시장 : 구성 요소별, 검사 유형별, 검체 유형별, 연령층별, 질환 유형별, 최종사용자별 - 세계 시장 예측(2026-2032년)

The Respiratory Disease Testing Market is projected to grow by USD 9.32 billion at a CAGR of 6.50% by 2032.

Introduction

Respiratory disease testing has become a core pillar of clinical decision-making, public health surveillance, antimicrobial stewardship, and outbreak preparedness. Demand is supported by the persistent burden of influenza, respiratory syncytial virus (RSV), tuberculosis, COVID-19, pneumonia, asthma and COPD exacerbations, and emerging respiratory pathogens. The World Health Organization reports tuberculosis remains one of the world's leading infectious disease killers, with an estimated 10.8 million people developing TB in 2023, underscoring the ongoing need for rapid, accurate respiratory diagnostics.

The market is shifting from centralized, single-pathogen testing toward integrated molecular panels, point-of-care antigen and molecular platforms, syndromic testing, and digitally connected diagnostics. Hospitals, reference laboratories, urgent care centers, pharmacies, and home-care settings are increasingly evaluating respiratory disease testing solutions based on speed, sensitivity, workflow efficiency, reimbursement fit, specimen type, and the ability to support surveillance reporting.

Transformative Shifts in the Respiratory Testing Landscape

The respiratory disease testing landscape is being reshaped by the normalization of molecular diagnostics after the COVID-19 pandemic, expanded multiplex PCR adoption, and rising demand for decentralized testing. Clinical buyers are prioritizing platforms that can differentiate viral and bacterial etiologies quickly, reducing inappropriate antibiotic use and improving patient triage during seasonal surges.

A second transformative shift is the convergence of diagnostics with digital health infrastructure. Laboratories and providers are integrating respiratory test results with electronic health records, public health reporting systems, and population-level dashboards. This creates competitive advantage for solutions that combine analytical accuracy with connectivity, automation, sample-to-answer workflows, and scalable supply chains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across respiratory disease testing by improving image interpretation, symptom triage, laboratory workflow optimization, epidemiological forecasting, and quality control. AI-enabled chest imaging tools can help prioritize suspected pneumonia, tuberculosis, and COVID-19 cases, while machine learning models support earlier detection of outbreak signals from testing volumes, positivity rates, syndromic data, and wastewater surveillance inputs.

The most commercially relevant AI use cases are those that reduce operational burden without replacing laboratory-grade validation. In practice, AI strengthens demand forecasting, reagent inventory planning, result interpretation support, and clinical decision support when paired with regulated diagnostic platforms. Industry leaders must ensure models are transparent, validated across diverse populations, and aligned with privacy, cybersecurity, and medical device regulations.

Key Regional Insights

Asia-Pacific is one of the most dynamic regions for respiratory disease testing due to large patient populations, high tuberculosis burden in several countries, urban air pollution, aging demographics in developed markets, and expanding healthcare access. China, India, Japan, South Korea, and Australia are investing in molecular diagnostics, public health surveillance, and hospital laboratory modernization, while Southeast Asian markets are increasing adoption of rapid tests for influenza, COVID-19, RSV, and TB screening in both centralized and community settings.

North America remains a high-value region driven by established reimbursement pathways, advanced molecular testing capacity, strong hospital networks, and high awareness of respiratory viruses. Latin America is expanding diagnostic access through public procurement, private laboratory networks, and infectious disease surveillance programs, with Brazil and Mexico serving as major demand centers. Europe benefits from strong regulatory oversight, mature laboratory infrastructure, antimicrobial resistance initiatives, and coordinated surveillance through national agencies and the European Centre for Disease Prevention and Control.

The Middle East is investing in hospital modernization, medical tourism infrastructure, and national preparedness programs, particularly across Gulf markets where advanced laboratory platforms are increasingly embedded in tertiary care systems. Africa presents significant long-term need because of the high burden of TB, pneumonia, HIV-associated respiratory infections, and limited laboratory access in many countries; scalable point-of-care testing, specimen referral networks, mobile diagnostics, and donor-supported programs are central to improving diagnostic coverage.

Key Group Insights

ASEAN markets are characterized by diverse healthcare systems, rising urbanization, cross-border mobility, and growing demand for affordable respiratory diagnostics that can operate in both hospital and decentralized settings. The GCC is accelerating adoption of advanced molecular platforms through healthcare transformation programs, centralized procurement, digital health investment, and expansion of high-acuity hospitals.

The European Union supports respiratory disease testing through harmonized regulatory frameworks, antimicrobial resistance strategies, clinical laboratory quality standards, and cross-border surveillance capacity. BRICS economies collectively represent large-volume opportunities because of population scale, infectious disease burden, expanding domestic manufacturing capabilities, and growing investment in public health laboratories. G7 countries remain innovation hubs for multiplex molecular testing, companion digital tools, regulatory science, and reimbursement-backed clinical adoption, while NATO-aligned health systems increasingly view respiratory pathogen detection as part of health security, military readiness, emergency preparedness, and continuity of essential services.

Key Country Insights

The United States leads in commercial adoption of multiplex respiratory panels, point-of-care molecular systems, and pharmacy-based testing expansion, supported by large laboratory networks, established coding pathways, and strong seasonal demand. Canada emphasizes public health testing, equitable access, and provincial procurement models, while Mexico is expanding private diagnostics and public surveillance capacity. Brazil is a key Latin American demand center, with testing shaped by urban population density, influenza seasonality, TB burden, and public-private laboratory expansion.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong respiratory testing ecosystems through national health systems, reference laboratories, and surveillance networks. Germany and France are particularly important for laboratory automation and molecular diagnostics, while the United Kingdom strengthened genomic and respiratory surveillance infrastructure after COVID-19. Russia remains relevant because of TB burden, respiratory infection surveillance needs, and domestic diagnostic capacity.

China and India are central to global testing volume due to population scale, TB and respiratory infection burden, air pollution-related respiratory illness, and expanding molecular testing infrastructure. Japan prioritizes high-quality diagnostics for aging populations and seasonal respiratory virus management, while South Korea combines strong biotechnology capacity with rapid adoption of advanced testing. Australia benefits from robust public health surveillance, hospital testing capacity, and demand for respiratory diagnostics across both urban centers and remote healthcare settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated respiratory disease testing portfolios that balance speed, accuracy, cost, and clinical utility. Multiplex panels should be aligned with local epidemiology, clinical guidelines, and reimbursement realities, while point-of-care platforms should be designed for simple workflows, minimal hands-on time, broad specimen compatibility, and reliable performance during seasonal demand spikes.

Organizations should strengthen supply chain resilience for swabs, reagents, cartridges, controls, and critical plastics; invest in interoperability with laboratory information systems and electronic health records; and build evidence packages that demonstrate reduced time to diagnosis, improved patient isolation decisions, fewer unnecessary antibiotics, and better antimicrobial stewardship. Partnerships with hospitals, public health agencies, pharmacies, primary care networks, and telehealth providers can accelerate access while improving surveillance value.

Research Methodology

This executive summary is developed using a structured secondary research methodology that triangulates information from public health agencies, regulatory bodies, peer-reviewed literature, clinical guidelines, and international disease surveillance sources. Key reference points include the World Health Organization, U.S. Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, national health ministries, and published diagnostic performance studies.

Market interpretation applies qualitative and quantitative validation across disease burden, testing settings, technology adoption, reimbursement dynamics, procurement behavior, regulatory pathways, and regional healthcare infrastructure. Insights are reviewed for consistency, recency, and relevance to respiratory disease testing, with emphasis on verified trends, epidemiological evidence, and clinically validated diagnostic use cases rather than speculative claims.

Conclusion

Respiratory disease testing is evolving into a connected, multi-technology ecosystem that supports faster diagnosis, better treatment decisions, stronger antimicrobial stewardship, and more resilient public health response. The market's next phase will be defined by multiplex molecular adoption, decentralized access, AI-supported workflows, and integration with surveillance systems.

Organizations that combine clinically validated assays, scalable manufacturing, digital connectivity, regulatory discipline, and region-specific commercialization strategies will be best positioned to capture growth opportunities. As respiratory pathogens continue to create seasonal, endemic, and pandemic risks, accurate and accessible testing will remain essential to healthcare resilience worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Respiratory Disease Testing Market, by Component

• 7.1. Instruments
• 7.2. Reagents & Kits
• 7.3. Software
• 7.4. Services

8. Respiratory Disease Testing Market, by Test Type

• 8.1. Molecular Diagnostics
  • 8.1.1. Polymerase Chain Reaction (PCR)
  • 8.1.2. Next Generation Sequencing (NGS)
  • 8.1.3. Loop Mediated Isothermal Amplification (LAMP)
• 8.2. Imaging Tests
  • 8.2.1. Chest X Ray
  • 8.2.2. Computed Tomography
  • 8.2.3. Magnetic Resonance Imaging (MRI)
  • 8.2.4. Positron Emission Tomography (PET)
• 8.3. Immunoassays
  • 8.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
  • 8.3.2. Chemiluminescence Immunoassay (CLIA)
  • 8.3.3. Fluorescence Immunoassay
  • 8.3.4. Radioimmunoassay (RIA)
• 8.4. Pulmonary Function Tests
  • 8.4.1. Spirometry
  • 8.4.2. Peak Flow Meter
  • 8.4.3. Diffusion Capacity Test (DLCO)
• 8.5. Point of Care Testing (POCT)

9. Respiratory Disease Testing Market, by Sample Type

• 9.1. Respiratory Specimens
  • 9.1.1. Sputum
  • 9.1.2. Bronchoalveolar Lavage (BAL)
  • 9.1.3. Tracheal Aspirate
  • 9.1.4. Nasopharyngeal Swab
• 9.2. Blood Based Samples
  • 9.2.1. Whole Blood
  • 9.2.2. Serum
  • 9.2.3. Plasma
• 9.3. Pleural Fluid

10. Respiratory Disease Testing Market, by Age Group

• 10.1. Adults
• 10.2. Geriatrics
• 10.3. Pediatrics

11. Respiratory Disease Testing Market, by Diseases Type

• 11.1. Viral Respiratory Diseases
  • 11.1.1. COVID 19
  • 11.1.2. Influenza Infections
    • 11.1.2.1. Influenza A
    • 11.1.2.2. Influenza B
  • 11.1.3. Rhinovirus Infection
  • 11.1.4. Adenovirus Infection
• 11.2. Bacterial Respiratory Diseases
  • 11.2.1. Mycobacterium Tuberculosis Infection
  • 11.2.2. Streptococcus Pneumoniae Infection
  • 11.2.3. Haemophilus Influenzae Infection
  • 11.2.4. Legionella Pneumophila Infection
• 11.3. Fungal Respiratory Diseases
  • 11.3.1. Aspergillus Infection
  • 11.3.2. Cryptococcus Infection
  • 11.3.3. Histoplasma Infection

12. Respiratory Disease Testing Market, by End Users

• 12.1. Diagnostic Laboratories
• 12.2. Home Care Settings
• 12.3. Hospitals & Clinics
• 12.4. Research Laboratories

13. Respiratory Disease Testing Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Respiratory Disease Testing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Respiratory Disease Testing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Becton, Dickinson and Company
• 17.3. Bio-Rad Laboratories, Inc.
• 17.4. bioMerieux SA
• 17.5. COSMED Srl
• 17.6. Danaher Corporation
• 17.7. DiaSorin S.p.A.
• 17.8. Dragerwerk AG & Co. KGaA
• 17.9. F. Hoffmann-La Roche Ltd.
• 17.10. Fisher & Paykel Healthcare Corporation Limited
• 17.11. GE HealthCare Technologies Inc.
• 17.12. Hologic, Inc.
• 17.13. Masimo Corporation
• 17.14. Medtronic plc
• 17.15. MGC Diagnostics Corporation
• 17.16. NDD Medical Technologies
• 17.17. Owlstone Medical Ltd.
• 17.18. QIAGEN N.V.
• 17.19. QuidelOrtho Corporation
• 17.20. Randox Laboratories Ltd.
• 17.21. ResMed Inc.
• 17.22. Seegene Inc.
• 17.23. Siemens Healthineers AG
• 17.24. Sysmex Corporation
• 17.25. Thermo Fisher Scientific Inc.
• 17.26. Verisante Technology, Inc.
• 17.27. Visby Medical, Inc.
• 17.28. Vyaire Medical Inc.